Onconetix, Inc.
About Onconetix, Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $815.4K
- Net income
- -$14.0M
- Total assets
- $24.9M
- Market cap
- $1.2M
Source: SEC EDGAR · updated Jun 8, 2026
- Market cap
- $1.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 18, 2022
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review Onconetix, Inc..